Document:

License Agreement

 Exhibit 10.10 
  
 LICENSE AGREEMENT 
  
 This Agreement is effective as of the latest date of signing below and is by and between Brookhaven Science Associates, LLC. (“Licensor”),
operator of Brookhaven National Laboratory, Upton, New York 11973, under contract with the U.S. Department of Energy, and Phage Biotechnology Corporation, having a principal place of business at 101 Theory, Suite 200, Irvine, CA 92617
(“Licensee”). 
  
 Licensor represents that it is the
owner of United States Patents No. 4,952,496 issued August 28, 1990, No. 5,693,489 issued December 2, 1997 and No. 5,869,320 issued February 9, 1999 in the names of F. William Studier, Parichehre Davanloo, Alan H.
Rosenberg, Barbara Moffatt and John J. Dunn entitled, “Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase”, and any patent(s) that may reissue therefrom and any foreign counterpart patents that may issue thereon
(“Patent Properties”), and has the right to grant the license herein granted; 
  
 Licensee desires to secure a non-exclusive license under the aforesaid Patent Properties to use the T7 technology covered by said Patent Properties in the conduct of its own research, and Licensor is willing to grant
the same on the terms and conditions set forth herein; Accordingly, in consideration of the premises and the mutual covenants of this Agreement, the parties hereto agree as follows: 
  
 I - GRANT 
  

(a) Subject to the rights of the U.S. Government, defined in Public Law 98-620 and the implementing regulations at 37CFR Part 401, Licensor hereby
grants to Licensee, a non exclusive license under the aforesaid Patent Properties to use said T7 technology in the conduct 
  
 BNL Model 9/04 (T7 Research Use) 

	Phage	Biotechnology Corporation (12/14/04)

  

 1 

 of its own in-house research, which does not involve human use. No other use or right is hereby licensed under said
Patent Properties. A separate license is required for use of the T7 technology covered by the Patent Properties for any commercial purpose, including but not limited to: 
  
 (1) use of the T7 technology to produce a product, which product the Licensee will sell or use commercially; 
  
 (2) use of a product produced using the T7 technology to screen compounds,
including DNA libraries, which compounds the Licensee is investigating for commercial use; 
  
 (3) use of a product produced using the T7 technology in a manufacturing process to convert intermediate products into end products, which end products the Licensee will sell or use commercially; 
  
 (4) use of the T7 technology to produce a product in greater quantities than
would be needed to meet the research needs of the Licensee, which product the Licensee will use in its day-to-day operations instead of obtaining the product from an outside source; 
  
 (5) the distribution, sale or other transfer of recombinant expression plasmids embodying the T7 technology to third
parties; and, 
  
 (6) administration of a product produced using
the T7 technology to humans. 
  
 (b) Nothing herein shall be
construed to prevent Licensor from licensing any invention covered by the Patent Properties licensed hereunder to any other for the purpose of manufacturing, using or selling any such invention. 
  

 2 

 II - LICENSE FEE 
  
 (a) Licensee agrees to pay to Licensor, as initial consideration for this License Grant, Two Thousand U.S. Dollars
($2,000.00), payable within thirty (30) days of the effective date of this Agreement. Licensee further agrees to pay an annual license fee of Two Thousand U.S. Dollars ($2,000.00), payable on the respective anniversary of the effective date of
this Agreement. 
  
 (b) All amounts payable hereunder shall be
payable in United States dollars without deductions for taxes, assessments, fees or charges of any kind. Checks shall be made payable to Brookhaven Science Associates, LLC. and mailed to Margaret C. Bogosian, Manager, Office of Intellectual Property
and Sponsored Research, Brookhaven National Laboratory, Bldg. 475D, P.O. Box 5000, Upton, New York 11973-5000. 
  
 III - DISCLAIMER. INDEMNIFICATION AND HOLD HARMLESS 
  
 (a) Licensor makes no representation or warranty, either expressed or implied, and no representation or warranty shall be
implied with respect to the License herein granted other than that Licensor has the right to grant said license. 
  
 (b) Nothing in this Agreement shall be construed as: 
  
 (1) a warranty or representation by Licensor as to the validity or scope of any Patent Properties; 
  
 (2) a warranty or representation that any product made or used or any method
practiced under this License Agreement is or will be free from infringement or claims of infringement of patents, copyrights or any other property right of third parties; or 
  
 (3) granting by implication, estoppel or otherwise any licenses or rights under patents or other property rights of Licensor
other than said Patent Properties, regardless of whether such patents are dominant or subordinate to any Patent Properties. 
  

 3 

 (c) Licensor shall not be liable for any injuries, losses or damages, including special or consequential
damages or losses incurred by Licensee, nor for claims for such damages, losses or other injuries asserted or levied against Licensee, arising out of Licensee’s practice of the Grant set forth in Article I of this Agreement. Licensee shall
indemnify and hold harmless Licensor and the U.S. government from any claims, actions, judgements or awards arising out of Licensee’s practice ofthe Grant set forth in Article I. 
  
 (d) Licensor shall not be obligated to prosecute against any third party any suit for infringement of the aforesaid Patent
Properties, licensed by it under this Agreement. 
  
 IV - SUCCESSOR RIGHTS 
  
 (a) The obligations of
Licensee hereunder shall run in favor of the successors, assigns or other legal representatives of Licensor. 
  
 (b) Licensee’s rights under this Agreement and the license herein granted shall not be assigned for the benefit of creditors of Licensee.
Licensee’s rights under this Agreement and the license granted herein may be assigned by Licensee to a corporation succeeding to the entire business and good will of Licensee as the result of a sale, consolidation, reorganization or otherwise,
provided such person or corporation shall, without delay accept in writing the provisions of this Agreement and agree to become in all respects bound thereby in the place and stead of Licensee. Licensee’s rights under this Agreement and the
license herein granted shall not be otherwise transferred without the written consent of Licensor. 
  
 V - TERMINATION 
  
 (a) If Licensee shall default in the payment of any License Fee, or shall commit any breach of any covenant herein contained, and shall fail to remedy any
such default or breach 
  

 4 

 within thirty (30) days after written notice thereof by Licensor, then Licensor may, at its option, terminate the
license and all other rights herein granted, by giving notice in writing to such effect. 
  
 (b) Licensee may terminate this license by giving sixty (60) days written notice of such termination. Such termination shall not serve to pro-rate or otherwise diminish the License Fee for the year in which the
notice is given. 
  
 (c) Unless previously terminated in
accordance with the foregoing provisions of this Article, this Agreement, the license granted to Licensee under the aforesaid Patent Properties and all of the rights granted to Licensee, shall become effective as of the date set forth at the outset
of this Agreement and shall run to the full end of the term of the last to expire patent in the Patent Properties licensed hereunder, and shall thereupon expire. 
  
 VI - ADVERTISING 
  
 Neither the granting of the license herein granted by Licensor, nor the acceptance of the license fees hereunder by
Licensor, shall constitute Licensor’s approval of, or acquiescence in, advertising or other business practices of Licensee, nor an approval of or acquiescence in any use of the corporate name of Licensor, or any use of the name Brookhaven
National Laboratory, or any use of the names of the inventors on the Patent Properties licensed hereunder, or any use of names of any agencies of the U.S. Government, in connection with the advertising of Licensee’s products, and Licensor
hereby expressly reserves all rights of actions with respect thereto. Licensee must obtain prior written approval from Licensor before using Licensor’s name in any advertising, press release, or other business materials to be publicly
distributed by Licensee. 
  

 5 

 VII - NOTICES 
  
 Any notice pursuant to this Agreement shall be sufficiently made or given on the date of mailing if sent to a party by
certified mail, postage prepaid, addressed to it at its address below: 
  
 For Licensor: 
  
 Margaret C. Bogosian, Manager 
 Office of Intellectual Property and Sponsored Research Brookhaven National
Laboratory 
 Building No. 475D 
 P.O. Box 5000 
 Upton, New York 11973-5000 
 Telephone: (631) 344-7338 
 Fax: (631) 344-3729 
 E-mail: ott@bnl.gov 
  
 For Licensee: 
  
 Dr. John Guastella 
 Director, Scientific Operations 
 Phage Biotechnology Corporation 
 101 Theory 
 Suite 200 
 Irvine, CA 92617 
 Telephone: (949) 823-9450 
 Fax: (949) 823-9459 
 E-mail: jguastella@phageboitech.com 
  
 Alternatively, such notices may be delivered to such other address or addresses as either Licensor or Licensee, respectively, may later establish by
written notice to the other. 
  
 VIII - UNITED
STATES GOVERNMENT EXPORT CONTROL REGULATIONS 
  
 (a) The
Export Control Regulations of the U.S. Department of Commerce prohibit, except under a special validated license, the exportation from the United States of technical data relating to certain commodities listed in the Regulations, unless the exporter
has received certain written assurance from the foreign importer. Licensee therefor hereby gives its assurance to Licensor that it will comply with all of the requirements of the U.S. Export Control Regulations. 
  
 (b) Violation of the U.S. Export Control laws or regulations by Licensee
shall constitute grounds for Licensor, in its sole discretion, to terminate this license Agreement. 
  

 6 

 Failure to obtain any needed export control license may result in criminal liability under the United States law.

  
 IX – APPLICABLE LAW 

 
 This Agreement shall be construed, interpreted and applied in
accordance with the laws of the United States and of the State of New York. 
  
 The parties hereto have duly executed this Agreement. 
  
 LICENSOR: 
  

			
	 	 	BROOKHAVEN SCIENCE ASSOCIATION
		
	By	 	  

	 	 	Margaret C. Bogosian
	Title	 	Manager, Office of Intellectual
	 	 	Property and Sponsored Research
		
	Date	 	  

	
	LICENSEE:
		
	 	 	PHAGE BIOTECHNOLOGY CORPORATION
		
	By	 	  

	Title	 	  

	Date	 	  

  

 7Service Agreement

 EXHIBIT 10.11 
  
 SERVICE AGREEMENT 
  
 This agreement entered into by and between Phage Biotechnology Inc., a Delaware corporation (“Phage” or “the Company”) and BS Biology
Sciences Limited, a Cyprus Corporation (“Service Provider). 
  
 RECITAL 
  

	 	A.	The Company and the Service Provider intend to jointly develop research for Phage Biotechnology Inc., that is proprietary and confidential. 

  

	 	B.	Phage will own all findings and discoveries under this Service Agreement. 

  
 NOW THEREFORE, in consideration of these premises and for the mutual promises and Covenants herein, it is hereby agreed as follows: 
  

	1.	The Service Provider will provide research and development expertise (“the Services”) to the Company through its facilities and relationships in Eastern Europe, and any
associated persons that the Service Provider deems necessary to accomplish the goals and tasks assigned by Phage. 

  

	2.	For the provision of these services, Phage will pay the Service Provider $243,622.00. 

  

	3.	Ownership of all findings, discoveries, data in both written and electronic format shall be the sole property of Phage. Such information shall be maintained confidential and
proprietary with any dissemination of such information be conducted only upon the written authorization of an officer of Phage. 

  

	4.	This agreement may be terminated by Phage for the following reasons; 

  
 a. Failure to Perform. In the event that the Service Provider does not perform or meet the established goals set by Phage, then this
agreement may be terminated through proper written notification with 60 day(s) notice. 
  
 b. Breach of Confidentiality. In the event that there is a breach of confidentiality, Phage may terminate this agreement with property
written notification with 60 day(s) notice. 
  
 c. Failure to Pay. In the event that Phage fails to pay monthly invoices, or reimburse expenses within 60 days of receipt, the Service Provider may terminate this agreement. 
  

	5.	The goals and tasks assigned to the Service Provider shall be submitted by Phage in writing with an appropriate time line for accomplishment thereof. Compensation will then be
negotiated and determined between the two parties. 

  

	6.	This Agreement shall be governed by California law. 

  

	7.	This Agreement contains the full and complete understanding of the parties with respect to the subject matter hereof and supersedes all prior representations and understandings,
whether oral, or written. This Agreement shall not be modified in any manner except by written amendment executed by each of the parties hereto. 

  

	8.	If any party hereto incurs legal fees, whether or not action is instituted to enforce the terms of this Agreement, the prevailing party shall be entitled to all attorney’s fees
in addition to other relief to which it or they may be entitled. 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of this 20TH day of December 2000 and agree to the above terms and acknowledge receipt of a copy of this Agreement. 
  

					
	 Phage Biotechnology Inc.,
	 	 	 	 “BS Biology Sciences, “SERVICE PROVIDER

			
	 /s/    Judith S. Pelton
	 	 	 	 /s/    Sergiy Buryak

	 Judith S. Pelton
	 	 	 	 Sergiy Buryak

	 Corporate Secretary
	 	 	 	 Owner

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]